GlycoMimetics Stock Price, News & Analysis (NASDAQ:GLYC)

$12.27 0.09 (0.74 %)
(As of 11/18/2017 04:00 PM ET)
Previous Close$12.27
Today's Range$12.45 - $11.93
52-Week Range$3.82 - $16.94
Volume177,440 shs
Average Volume555,939 shs
Market Capitalization$421.33 million
P/E RatioN/A
Dividend YieldN/A
Beta3.14

About GlycoMimetics (NASDAQ:GLYC)

GlycoMimetics logoGlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:GLYC
  • CUSIP: N/A
  • Web: www.glycomimetics.com
Debt:
  • Current Ratio: 17.44%
  • Quick Ratio: 17.44%
Sales & Book Value:
  • Annual Sales: $20,000.00
  • Price / Sales: 21,067.59
  • Book Value: $1.53 per share
  • Price / Book: 8.02
Profitability:
  • Trailing EPS: ($1.24)
  • Net Income: ($31,800,000.00)
  • Return on Equity: -44.45%
  • Return on Assets: -40.83%
Misc:
  • Employees: 42
  • Outstanding Shares: 34,340,000
 

Frequently Asked Questions for GlycoMimetics (NASDAQ:GLYC)

What is GlycoMimetics' stock symbol?

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

How were GlycoMimetics' earnings last quarter?

GlycoMimetics, Inc. (NASDAQ:GLYC) posted its quarterly earnings data on Wednesday, November, 8th. The biotechnology company reported ($0.24) EPS for the quarter, topping the Zacks' consensus estimate of ($0.28) by $0.04. View GlycoMimetics' Earnings History.

Where is GlycoMimetics' stock going? Where will GlycoMimetics' stock price be in 2017?

6 Wall Street analysts have issued 12 month target prices for GlycoMimetics' stock. Their forecasts range from $12.00 to $25.00. On average, they anticipate GlycoMimetics' stock price to reach $18.20 in the next twelve months. View Analyst Ratings for GlycoMimetics.

What are Wall Street analysts saying about GlycoMimetics stock?

Here are some recent quotes from research analysts about GlycoMimetics stock:

  • 1. According to Zacks Investment Research, "GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States. " (11/13/2017)
  • 2. Cowen and Company analysts commented, "GLYC’s GMI-1271, an E-selectin antagonist, in a Ph1/2 AML trial, has generated very." (5/9/2017)

Who are some of GlycoMimetics' key competitors?

Who are GlycoMimetics' key executives?

GlycoMimetics' management team includes the folowing people:

  • M. James E. Barrett Ph.D., Independent Chairman of the Board (Age 74)
  • Rachel K. King, President, Chief Executive Officer, Co-Founder, Director (Age 57)
  • John Magnani Ph.D., Co-Founder, Senior Vice President, Chief Scientific Officer, Director (Age 64)
  • Brian Hahn, Chief Financial Officer (Age 42)
  • Helen M. Thackray M.D., , Senior Vice President - Clinical Development, Chief Medical Officer (Age 47)
  • Patricia S. Andrews, Director
  • Mark Alan Goldberg M.D., Independent Director (Age 62)
  • Daniel M. Junius, Independent Director (Age 64)
  • Scott Koenig M.D., Ph.D., Independent Director (Age 64)
  • Timothy R. Pearson, Independent Director (Age 49)

Who owns GlycoMimetics stock?

GlycoMimetics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (1.42%), EAM Investors LLC (1.13%), Alyeska Investment Group L.P. (1.05%), Columbus Circle Investors (0.62%), Citadel Advisors LLC (0.18%) and TD Asset Management Inc. (0.08%). Company insiders that own GlycoMimetics stock include Daniel M Junius, Helen M Thackray and Mark Alan Goldberg. View Institutional Ownership Trends for GlycoMimetics.

Who sold GlycoMimetics stock? Who is selling GlycoMimetics stock?

GlycoMimetics' stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC and TD Asset Management Inc.. View Insider Buying and Selling for GlycoMimetics.

Who bought GlycoMimetics stock? Who is buying GlycoMimetics stock?

GlycoMimetics' stock was bought by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Citadel Advisors LLC, EAM Investors LLC, Fox Run Management L.L.C., Alyeska Investment Group L.P. and Dynamic Technology Lab Private Ltd. Company insiders that have bought GlycoMimetics stock in the last two years include Daniel M Junius and Mark Alan Goldberg. View Insider Buying and Selling for GlycoMimetics.

How do I buy GlycoMimetics stock?

Shares of GlycoMimetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GlycoMimetics' stock price today?

One share of GlycoMimetics stock can currently be purchased for approximately $12.27.

How big of a company is GlycoMimetics?

GlycoMimetics has a market capitalization of $421.33 million and generates $20,000.00 in revenue each year. The biotechnology company earns ($31,800,000.00) in net income (profit) each year or ($1.24) on an earnings per share basis. GlycoMimetics employs 42 workers across the globe.

How can I contact GlycoMimetics?

GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected]


MarketBeat Community Rating for GlycoMimetics (NASDAQ GLYC)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  148 (Vote Outperform)
Underperform Votes:  91 (Vote Underperform)
Total Votes:  239
MarketBeat's community ratings are surveys of what our community members think about GlycoMimetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for GlycoMimetics (NASDAQ:GLYC)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 6 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $18.20 (48.33% upside)

Consensus Price Target History for GlycoMimetics (NASDAQ:GLYC)

Price Target History for GlycoMimetics (NASDAQ:GLYC)

Analysts' Ratings History for GlycoMimetics (NASDAQ:GLYC)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/26/2017Jefferies Group LLCReiterated RatingBuy$16.00N/AView Rating Details
10/23/2017Roth CapitalInitiated CoverageBuy$25.00N/AView Rating Details
10/4/2017SunTrust Banks, Inc.Reiterated RatingBuy$21.00N/AView Rating Details
8/4/2017Stifel NicolausReiterated RatingBuy$13.00 -> $17.00LowView Rating Details
5/28/2017Cowen and CompanyReiterated RatingOutperformLowView Rating Details
5/19/2017Canaccord GenuityReiterated RatingBuy$12.00HighView Rating Details
(Data available from 11/19/2015 forward)

Earnings

Earnings History and Estimates Chart for GlycoMimetics (NASDAQ:GLYC)

Earnings by Quarter for GlycoMimetics (NASDAQ:GLYC)

Earnings History by Quarter for GlycoMimetics (NASDAQ GLYC)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.28)($0.24)ViewN/AView Earnings Details
8/3/2017Q2 2017($0.37)($0.30)ViewN/AView Earnings Details
5/8/2017Q1 2017($0.37)($0.34)ViewN/AView Earnings Details
3/1/2017Q4 2016($0.35)($0.36)$4.50 millionViewN/AView Earnings Details
11/4/2016Q216($0.44)($0.34)$0.02 millionViewN/AView Earnings Details
5/4/2016Q116($0.47)($0.40)ViewN/AView Earnings Details
2/29/2016Q4($0.38)($0.47)$35.00 millionViewN/AView Earnings Details
11/12/2015Q3($0.40)($0.38)$2.10 millionViewN/AView Earnings Details
8/6/2015Q2 2015($0.40)$0.51$20.04 millionViewN/AView Earnings Details
3/16/2015Q4 2014($0.22)($0.39)ViewN/AView Earnings Details
10/31/2014Q314$0.21($0.35)$10.00 millionViewN/AView Earnings Details
7/31/2014Q2 2014$0.24$0.39$9.08 million$15.03 millionViewN/AView Earnings Details
5/8/2014Q114($0.28)($0.30)ViewN/AView Earnings Details
3/31/2014($2.17)($2.80)$9.65 million$0.08 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for GlycoMimetics (NASDAQ:GLYC)
2017 EPS Consensus Estimate: ($1.32)
2018 EPS Consensus Estimate: ($0.43)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.38)($0.37)($0.38)
Q2 20172($0.40)($0.30)($0.35)
Q3 20172($0.43)($0.25)($0.34)
Q4 20172($0.26)($0.25)($0.26)
Q1 20182($0.27)($0.25)($0.26)
Q2 20182($0.29)($0.27)($0.28)
Q3 20182($0.33)($0.30)($0.32)
Q4 20182($0.31)$1.16$0.43
(Data provided by Zacks Investment Research)

Dividends

Dividend History for GlycoMimetics (NASDAQ:GLYC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for GlycoMimetics (NASDAQ GLYC)

Insider Ownership Percentage: 43.80%
Institutional Ownership Percentage: 88.32%
Insider Trades by Quarter for GlycoMimetics (NASDAQ:GLYC)
Institutional Ownership by Quarter for GlycoMimetics (NASDAQ:GLYC)

Insider Trades by Quarter for GlycoMimetics (NASDAQ GLYC)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/18/2017Helen M ThackraySVPSell2,000$13.00$26,000.00View SEC Filing  
5/25/2017Helen M ThackraySVPSell2,000$15.57$31,140.00View SEC Filing  
5/19/2017Helen M ThackraySVPSell2,000$12.14$24,280.00View SEC Filing  
12/20/2016Daniel M. JuniusDirectorBuy5,000$6.01$30,050.00View SEC Filing  
10/3/2016Helen M ThackrayVPSell4,000$7.00$28,000.00View SEC Filing  
7/20/2016Helen M ThackrayVPSell2,000$8.00$16,000.00View SEC Filing  
7/6/2016Helen M ThackrayCMOSell22,000$7.00$154,000.00View SEC Filing  
3/4/2016Mark Alan GoldbergDirectorBuy10,397$4.77$49,593.69View SEC Filing  
12/22/2014Michael A HenosDirectorSell21,257$8.52$181,109.64View SEC Filing  
12/17/2014Michael A HenosDirectorSell6,725$8.97$60,323.25View SEC Filing  
12/15/2014Michael A HenosDirectorSell1,604$8.98$14,403.92View SEC Filing  
6/13/2014Michael A HenosDirectorBuy11,000$6.39$70,290.00View SEC Filing  
1/15/2014Enterprise Associates 13 L NewMajor ShareholderBuy512,500$8.00$4,100,000.00View SEC Filing  
1/15/2014M James BarrettDirectorBuy1,000,000$8.00$8,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for GlycoMimetics (NASDAQ GLYC)

Source:
DateHeadline
Selectin Inhibition Justifies GlycoMimetics InvestmentSelectin Inhibition Justifies GlycoMimetics Investment
seekingalpha.com - November 16 at 2:46 PM
GlycoMimetics, Inc. (GLYC) Stock Rating Upgraded by Zacks Investment ResearchGlycoMimetics, Inc. (GLYC) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 13 at 11:46 PM
GlycoMimetics, Inc. (GLYC) Receives Consensus Rating of "Buy" from AnalystsGlycoMimetics, Inc. (GLYC) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - November 13 at 9:34 PM
SunTrust Banks Comments on GlycoMimetics, Inc.s Q1 2018 Earnings (GLYC)SunTrust Banks Comments on GlycoMimetics, Inc.'s Q1 2018 Earnings (GLYC)
www.americanbankingnews.com - November 13 at 6:00 AM
Jefferies Group Comments on GlycoMimetics, Inc.s FY2017 Earnings (GLYC)Jefferies Group Comments on GlycoMimetics, Inc.'s FY2017 Earnings (GLYC)
www.americanbankingnews.com - November 13 at 3:36 AM
Analyzing GlycoMimetics (GLYC) and Its PeersAnalyzing GlycoMimetics (GLYC) and Its Peers
www.americanbankingnews.com - November 12 at 11:54 PM
GlycoMimetics to Present at Upcoming Healthcare Investor Conferences - Business Wire (press release)GlycoMimetics to Present at Upcoming Healthcare Investor Conferences - Business Wire (press release)
www.businesswire.com - November 11 at 6:59 AM
GlycoMimetics, Inc. (GLYC) to Post Q1 2018 Earnings of ($0.25) Per Share, Jefferies Group ForecastsGlycoMimetics, Inc. (GLYC) to Post Q1 2018 Earnings of ($0.25) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - November 10 at 10:50 AM
GlycoMimetics, Inc. (GLYC) Posts Quarterly  Earnings Results, Beats Expectations By $0.04 EPSGlycoMimetics, Inc. (GLYC) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS
www.americanbankingnews.com - November 9 at 6:33 PM
GlycoMimetics Reports Program Updates and Third Quarter 2017 Results - Business Wire (press release)GlycoMimetics Reports Program Updates and Third Quarter 2017 Results - Business Wire (press release)
www.businesswire.com - November 9 at 6:09 AM
Edited Transcript of GLYC earnings conference call or presentation 8-Nov-17 1:30pm GMTEdited Transcript of GLYC earnings conference call or presentation 8-Nov-17 1:30pm GMT
finance.yahoo.com - November 9 at 6:09 AM
GlycoMimetics, Inc. to Host Earnings CallGlycoMimetics, Inc. to Host Earnings Call
finance.yahoo.com - November 8 at 8:05 AM
GlycoMimetics Reports Program Updates and Third Quarter 2017 ResultsGlycoMimetics Reports Program Updates and Third Quarter 2017 Results
finance.yahoo.com - November 8 at 8:05 AM
Why Earnings Season Could Be Great for GlycoMimetics (GLYC) - NasdaqWhy Earnings Season Could Be Great for GlycoMimetics (GLYC) - Nasdaq
www.nasdaq.com - November 2 at 8:53 PM
Why Earnings Season Could Be Great for GlycoMimetics (GLYC)Why Earnings Season Could Be Great for GlycoMimetics (GLYC)
finance.yahoo.com - November 2 at 8:53 PM
GlycoMimetics to Highlight GMI-1271 Clinical Data and Underlying, Differentiated Mechanism of Action in Oral Presentations at 59th Annual ASH MeetingGlycoMimetics to Highlight GMI-1271 Clinical Data and Underlying, Differentiated Mechanism of Action in Oral Presentations at 59th Annual ASH Meeting
finance.yahoo.com - November 1 at 8:43 PM
GlycoMimetics to Report Third-Quarter 2017 Financial Results on November 8, 2017GlycoMimetics to Report Third-Quarter 2017 Financial Results on November 8, 2017
finance.yahoo.com - November 1 at 8:43 PM
GlycoMimetics, Inc. (GLYC) Rating Reiterated by Jefferies Group LLCGlycoMimetics, Inc. (GLYC) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - October 26 at 2:44 PM
GlycoMimetics, Inc. (GLYC) Coverage Initiated by Analysts at Roth CapitalGlycoMimetics, Inc. (GLYC) Coverage Initiated by Analysts at Roth Capital
www.americanbankingnews.com - October 23 at 10:40 PM
GlycoMimetics, Inc. (GLYC) Given Average Rating of "Buy" by AnalystsGlycoMimetics, Inc. (GLYC) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - October 19 at 8:46 PM
GlycoMimetics, Inc. – Value Analysis (NASDAQ:GLYC) : October 17, 2017GlycoMimetics, Inc. – Value Analysis (NASDAQ:GLYC) : October 17, 2017
finance.yahoo.com - October 17 at 7:49 PM
GlycoMimetics, Inc. (GLYC) Lowered to Hold at Zacks Investment ResearchGlycoMimetics, Inc. (GLYC) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - October 16 at 11:20 PM
GlycoMimetics, Inc. breached its 50 day moving average in a Bearish Manner : GLYC-US : October 16, 2017GlycoMimetics, Inc. breached its 50 day moving average in a Bearish Manner : GLYC-US : October 16, 2017
finance.yahoo.com - October 16 at 3:48 PM
Head-To-Head Contrast: GlycoMimetics (GLYC) versus Its CompetitorsHead-To-Head Contrast: GlycoMimetics (GLYC) versus Its Competitors
www.americanbankingnews.com - October 16 at 2:10 AM
GlycoMimetics, Inc. (GLYC) Upgraded at Zacks Investment ResearchGlycoMimetics, Inc. (GLYC) Upgraded at Zacks Investment Research
www.americanbankingnews.com - October 6 at 11:14 PM
GlycoMimetics, Inc. (GLYC) Receives "Buy" Rating from SunTrust Banks, Inc.GlycoMimetics, Inc. (GLYC) Receives "Buy" Rating from SunTrust Banks, Inc.
www.americanbankingnews.com - October 4 at 9:14 PM
BRIEF-GlycoMimetics says files for mixed shelf of upto $250 mlnBRIEF-GlycoMimetics says files for mixed shelf of upto $250 mln
www.reuters.com - September 28 at 8:29 PM
GlycoMimetics (GLYC) in Focus: Stock Moves 9.2% HigherGlycoMimetics (GLYC) in Focus: Stock Moves 9.2% Higher
finance.yahoo.com - September 26 at 11:40 AM
GlycoMimetics Inc (GLYC) Receives Consensus Rating of "Hold" from BrokeragesGlycoMimetics Inc (GLYC) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - September 24 at 8:34 PM
GlycoMimetics, Inc. (GLYC) SVP Sells $26,000.00 in StockGlycoMimetics, Inc. (GLYC) SVP Sells $26,000.00 in Stock
www.americanbankingnews.com - September 18 at 8:10 PM
GlycoMimetics, Inc. breached its 50 day moving average in a Bearish Manner : GLYC-US : September 11, 2017GlycoMimetics, Inc. breached its 50 day moving average in a Bearish Manner : GLYC-US : September 11, 2017
finance.yahoo.com - September 11 at 7:37 PM
Can GlycoMimetics (GLYC) Run Higher on Strong Earnings Estimate Revisions?Can GlycoMimetics (GLYC) Run Higher on Strong Earnings Estimate Revisions?
finance.yahoo.com - September 6 at 1:26 AM
GlycoMimetics to Present at Biocentury’s Newsmakers in the Biotech Industry ConferenceGlycoMimetics to Present at Biocentury’s Newsmakers in the Biotech Industry Conference
finance.yahoo.com - September 6 at 1:26 AM
GlycoMimetics, Inc. (GLYC) Given Consensus Recommendation of "Hold" by AnalystsGlycoMimetics, Inc. (GLYC) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - August 30 at 8:36 PM
GlycoMimetics, Inc. breached its 50 day moving average in a Bullish Manner : GLYC-US : August 25, 2017GlycoMimetics, Inc. breached its 50 day moving average in a Bullish Manner : GLYC-US : August 25, 2017
finance.yahoo.com - August 26 at 3:21 AM
Q3 2017 Earnings Forecast for GlycoMimetics, Inc. (NASDAQ:GLYC) Issued By SunTrust BanksQ3 2017 Earnings Forecast for GlycoMimetics, Inc. (NASDAQ:GLYC) Issued By SunTrust Banks
www.americanbankingnews.com - August 9 at 8:08 AM
GlycoMimetics, Inc. breached its 50 day moving average in a Bullish Manner : GLYC-US : August 8, 2017GlycoMimetics, Inc. breached its 50 day moving average in a Bullish Manner : GLYC-US : August 8, 2017
finance.yahoo.com - August 8 at 6:48 PM
GlycoMimetics, Inc. (GLYC) Posts  Earnings Results, Beats Expectations By $0.07 EPSGlycoMimetics, Inc. (GLYC) Posts Earnings Results, Beats Expectations By $0.07 EPS
www.americanbankingnews.com - August 5 at 9:56 PM
GlycoMimetics, Inc. (NASDAQ:GLYC) Receives Average Recommendation of "Buy" from BrokeragesGlycoMimetics, Inc. (NASDAQ:GLYC) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 5 at 8:56 PM
 Brokerages Expect GlycoMimetics, Inc. (NASDAQ:GLYC) to Announce -$0.37 EPS Brokerages Expect GlycoMimetics, Inc. (NASDAQ:GLYC) to Announce -$0.37 EPS
www.americanbankingnews.com - August 5 at 12:44 PM
Stifel Nicolaus Reiterates Buy Rating for GlycoMimetics, Inc. (NASDAQ:GLYC)Stifel Nicolaus Reiterates Buy Rating for GlycoMimetics, Inc. (NASDAQ:GLYC)
www.americanbankingnews.com - August 5 at 11:34 AM
GlycoMimetics, Inc. – Value Analysis (NASDAQ:GLYC) : August 1, 2017GlycoMimetics, Inc. – Value Analysis (NASDAQ:GLYC) : August 1, 2017
finance.yahoo.com - August 1 at 7:41 PM
GlycoMimetics, Inc. breached its 50 day moving average in a Bullish Manner : GLYC-US : July 19, 2017GlycoMimetics, Inc. breached its 50 day moving average in a Bullish Manner : GLYC-US : July 19, 2017
finance.yahoo.com - July 19 at 7:45 PM
GlycoMimetics, Inc. (NASDAQ:GLYC) Given Average Rating of "Buy" by BrokeragesGlycoMimetics, Inc. (NASDAQ:GLYC) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 11 at 8:50 PM
FDA Issues an Approval Not Seen in Almost 20 YearsFDA Issues an Approval Not Seen in Almost 20 Years
247wallst.com - July 8 at 11:07 AM
BRIEF-GlycoMimetics Inc says to receive European patent for GMI-1271BRIEF-GlycoMimetics Inc says to receive European patent for GMI-1271
www.reuters.com - July 6 at 8:59 PM
GlycoMimetics to Receive European Patent for GMI-1271GlycoMimetics to Receive European Patent for GMI-1271
finance.yahoo.com - July 6 at 8:59 PM
BRIEF-Glycomimetics presents updated data from ongoing phase 1/2 clinical trial of GMI-1271 at ASCOBRIEF-Glycomimetics presents updated data from ongoing phase 1/2 clinical trial of GMI-1271 at ASCO
www.reuters.com - June 5 at 5:35 PM
ALBO Spikes, GLYC Abuzz, FDA Approves 1st Generic Strattera For ADHDALBO Spikes, GLYC Abuzz, FDA Approves 1st Generic Strattera For ADHD
www.rttnews.com - May 31 at 9:02 AM
GlycoMimetics (GLYC) Says GMI-1271 Received EU Orphan Drug Designation for AMLGlycoMimetics (GLYC) Says GMI-1271 Received EU Orphan Drug Designation for AML
www.streetinsider.com - May 25 at 7:52 PM

Social Media

Financials

Chart

GlycoMimetics (NASDAQ GLYC) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.